The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 7 events

2021-10-06Safety communicationSafety

Drug Safety Update: COVID-19 vaccines: updates for October 2021

Evidence ↗

2021-08-16Safety communicationSafety

Drug Safety Update: COVID-19 vaccines: updates for August 2021

Evidence ↗

2021-07-07Safety communicationSafety

Drug Safety Update: COVID-19 vaccines: updates for July 2021

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

27 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 27

Phase 14Phase 1 / 21Phase 24Phase 2 / 31Phase 36Phase 46Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Immunogenicity and Safety of Inactivated COVID-19 Vaccine Coadministered With 23-valent Pneumococcal Polysaccharide Vaccine and Quadrivalent Influenza Vaccine in Hemodialysis Population: a Multicentre, Randomised, Controlled, Phase 4 Trial

Unknown statusPH IVKey trialChina National Biotec Group Company Limitedn=1,2002023

Immunogenicity Study of the Covid-19 (Recombinante) Vaccine - Fiocruz/AstraZeneca When Administered With a 4 or 8 Weeks Interval Between the First Two Doses.

Unknown statusPH IVKey trialThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)n=1,2642023

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine in China: a Multicentre, Randomised, Controlled, Phase 4 Trial

Unknown statusPH IVChina National Biotec Group Company Limitedn=3602023

A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Wuhan): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes

Unknown statusPH IVKey trialChina National Biotec Group Company Limitedn=1,4402022

A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes

Unknown statusPH IVKey trialChina National Biotec Group Company Limitedn=1,4402022

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age

CompletedPH IIIKey trialModernaTX, Inc.n=2,4572025

A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

CompletedPH IIModernaTX, Inc.n=1,3202025

A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS

CompletedPH I/IIBioNTech SEn=1,3532025

A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS

CompletedPH IIIKey trialBioNTech SEn=8,7952024

Effects of Oral Iron Supplementation Before vs. at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

CompletedN/ANicole Stoffeln=1802024

A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

CompletedPH IIIKey trialModernaTX, Inc.n=8,0612024

Research activity

72 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20202025

Most influential

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

The New England journal of medicine · 2020 · 12,089 cites

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

The New England journal of medicine · 2021 · 8,675 cites

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020 · 5,232 cites

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Lancet (London, England) · 2021 · 3,723 cites

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.

Science (New York, N.Y.) · 2021 · 2,001 cites

SARS-CoV-2 vaccines in development.

Nature · 2020 · 1,566 cites

Related diseases

9 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

COVID-1962 Coronavirus Infections20 Pneumonia, Viral17 Neoplasms7 Severe Acute Respiratory Syndrome4 Disease Models, Animal3 Post-Acute COVID-19 Syndrome3 Communicable Diseases2 Communicable Diseases, Emerging2

Related drugs

7 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

BCG Vaccine

Studied across 7 of the same disease areas as COVID-19 Vaccines in the shared literature.

7 shared diseases1 shared paper

Liposomes

Studied across 2 of the same disease areas as COVID-19 Vaccines in the shared literature.

2 shared diseases4 shared papers

Influenza Vaccines

Studied across 4 of the same disease areas as COVID-19 Vaccines in the shared literature.

4 shared diseases2 shared papers

Aluminum Hydroxide

Studied across 3 of the same disease areas as COVID-19 Vaccines in the shared literature.

3 shared diseases1 shared paper

Propiolactone

Studied across 3 of the same disease areas as COVID-19 Vaccines in the shared literature.

3 shared diseases1 shared paper

ChAdOx1 nCoV-19

Studied across the same disease area as COVID-19 Vaccines in the shared literature.

1 shared disease3 shared papers

Ad26COVS1

Studied across the same disease area as COVID-19 Vaccines in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.